SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001839882-23-022729
Filing Date
2023-08-29
Accepted
2023-08-29 16:30:44
Documents
13
Period of Report
2023-08-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_082323.htm   iXBRL 8-K 39957
2 EXECUTIVE EMPLOYMENT AGREEMENT ex10-1.htm EX-10.1 98329
  Complete submission text file 0001839882-23-022729.txt   346121

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE admp-20230823.xsd EX-101.SCH 3054
4 XBRL LABEL FILE admp-20230823_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE admp-20230823_pre.xml EX-101.PRE 22385
7 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_082323_htm.xml XML 3313
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 231222316
SIC: 2834 Pharmaceutical Preparations